熱門資訊> 正文

BRIEF-Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia

2025-01-08 05:23

Jan 7 (Reuters) - Solid Biosciences Inc SLDB.O:

SOLID BIOSCIENCES ANNOUNCES FDA IND CLEARANCE FOR FIRST-IN-INDUSTRY DUAL ROUTE OF ADMINISTRATION GENE THERAPY TO TREAT BOTH NEUROLOGIC AND CARDIAC MANIFESTATIONS OF FRIEDREICH’S ATAXIA
SOLID BIOSCIENCES INC: PHASE 1B CLINICAL TRIAL INITIATION EXPECTED IN 2H 2025

Source text: ID:nGNXbQwqFD

Further company coverage: SLDB.O

((Reuters.Briefs@thomsonreuters.com;))

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。